Literature DB >> 16650651

Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Peter Y Liu1, Ronald S Swerdloff, Peter D Christenson, David J Handelsman, Christina Wang.   

Abstract

BACKGROUND: Hormonal methods for safe, reliable, and reversible contraception based on the suppression of spermatogenesis could soon become available. We have investigated the rate, extent, and predictors of reversibility of hormonal male contraception.
METHODS: We undertook an integrated multivariate time-to-event analysis of data from individual participants in 30 studies published in 1990-2005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility. We undertook univariate and multivariate analyses, using Kaplan-Meier and Cox's methods.
FINDINGS: 1549 healthy eugonadal men who were white (n=965), Asian (almost all Chinese men; n=535), or of other origins (n=49) and aged 18-51 years underwent 1283.5 man-years of treatment and 705 man-years of post-treatment recovery. These data represented about 90% of all published data from individuals using androgen or androgen-progestagen regimens. The median times for sperm to recover to thresholds of 20, 10, and 3 million per mL were 3.4 months (95% CI 3.2-3.5), 3.0 months (2.9-3.1), and 2.5 months (2.4-2.7), respectively. Multivariate Cox's analysis showed higher rates of recovery with older age, Asian origin, shorter treatment duration, shorter-acting testosterone preparations, higher sperm concentrations at baseline, faster suppression of spermatogenesis, and lower blood concentrations of luteinising hormone at baseline. The typical probability of recovery to 20 million per mL was 67% (61-72) within 6 months, 90% (85-93) within 12 months, 96% (92-98) within 16 months, and 100% within 24 months.
INTERPRETATION: Hormonal male contraceptive regimens show full reversibility within a predictable time course. Various covariables affect the rate but not the extent of recovery, although their effect sizes are minor. These data are crucial for the further safe and practical development of such regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650651     DOI: 10.1016/S0140-6736(06)68614-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  58 in total

1.  Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study.

Authors:  Nathaniel S Marshall; Keith K H Wong; Peter Y Liu; Stewart R J Cullen; Matthew W Knuiman; Ronald R Grunstein
Journal:  Sleep       Date:  2008-08       Impact factor: 5.849

2.  Simultaneous quantification of steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass spectrometry.

Authors:  Alissa Renne; Lindi Luo; Jonathan Jarow; William W Wright; Terry R Brown; Haolin Chen; Barry R Zirkin; Marlin D Friesen
Journal:  J Androl       Date:  2011-10-20

3.  [Hormonal contraception for men: still a current issue].

Authors:  M Zitzmann
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 4.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

5.  Azoospermia With Testosterone Therapy Despite Concomitant Intramuscular Human Chorionic Gonadotropin: NYU Case of the Month, July 2018.

Authors:  Bobby Najari
Journal:  Rev Urol       Date:  2018

6.  Hormonal male contraception: end of a dream or start of a new era?

Authors:  Eberhard Nieschlag
Journal:  Endocrine       Date:  2012-11-18       Impact factor: 3.633

Review 7.  Hormone-Based Treatments in Subfertile Males.

Authors:  Darshan P Patel; Jason C Chandrapal; James M Hotaling
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

8.  Recovery of Reproductive and Cardiac Function in Past Androgen Users.

Authors:  Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

9.  Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy.

Authors:  Taylor P Kohn; Matthew R Louis; Stephen M Pickett; Mark C Lindgren; Jaden R Kohn; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Fertil Steril       Date:  2016-11-14       Impact factor: 7.329

10.  Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.

Authors:  Robert A Stockley; David G Parr; Eeva Piitulainen; Jan Stolk; Berend C Stoel; Asger Dirksen
Journal:  Respir Res       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.